Figure 6b: Suppression of CRP after 12 weeks of sgp130Fc administration. Separate curves represent timing between doses. 
sgp130Fc is an antibody modified with sgp130, an endogenous Inhibitor and sequestration glycoprotein of the IL6/IL6Ra soluble complex.

Three separate simulations, one for each dose regimen, were carried out by parameter scan for Dose with 8 intervals between 0 and 2000 mg. Results plotted in libreCalc.